These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9771947)

  • 1. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents.
    van Hille B; Hill BT
    Cancer Chemother Pharmacol; 1998; 42(5):345-56. PubMed ID: 9771947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
    van Hille B; Clerc X; Creighton AM; Hill BT
    Br J Cancer; 1999 Nov; 81(5):800-7. PubMed ID: 10555749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
    Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
    Nitiss JL; Liu YX; Hsiung Y
    Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ; Newell DR; Calvert AH; Curtin NJ
    Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
    Wasserman RA; Wang JC
    Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
    Nitiss JL; Vilalta PM; Wu H; McMahon J
    Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast.
    Wasserman RA; Austin CA; Fisher LM; Wang JC
    Cancer Res; 1993 Aug; 53(15):3591-6. PubMed ID: 8393377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast.
    Keller BA; Patel S; Fisher LM
    Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):329-39. PubMed ID: 9164874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
    Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
    Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
    Nitiss JL; Liu YX; Harbury P; Jannatipour M; Wasserman R; Wang JC
    Cancer Res; 1992 Aug; 52(16):4467-72. PubMed ID: 1322791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
    Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
    Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.